ESMO 2023 | Questions following the DESTINY-Breast trials

Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, discusses the DESTINY-Breast-01—03 studies (NCT03248492, NCT03523585, NCT03529110), which identified trastuzumab deruxtecan as the new standard of care for patients with HER2+ breast cancer with treated and untreated brain metastasis. However, there remain significant unmet needs in these populations due to the heterogeneity of the disease, with outstanding questions concerning drug delivery and combination therapies such as those involving immunotherapy addition. Further challenges addressed relate to health economics, quality of life and accessibility, particularly in Asian populations. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.